undamentalytics Newsletter
Sign in

Precision Biosciences Inc (DTIL) stock

Add to watchlist

Add holding +

NASDAQ: DTIL Nasdaq Biotechnology Next results ~November 3, 2026

Precision Biosciences Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Precision Biosciences Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders3 buying, 4 selling6 purchases and 11 sales by directors and officers, last 12 monthsInsider trades
  • Funds61 adding, 27 cuttingOf 23 active managers that changed their stake, 10 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Precision Biosciences files

10-Q filed November 3: Precision Biosciences

Precision Biosciences posted revenue of $45m for the twelve months to September 2026, up 6353.0% on a year earlier. That pace accelerated from the 3473.0% growth recorded a quarter earlier. Margins also improved from deeply negative bases: the free-cash-flow margin rose to -115.0% from -10521.3%, while the operating margin widened to -80.3% from -12822.6%. Shareholders should note that the diluted share count climbed 72.5% over the year, diluting existing holders. Despite the improving trends, our model value has fallen, from $4.08 to $1.92 a share, well below the current share price of $6.95. The gap suggests the market is pricing in a more optimistic outcome than the model supports.

Our model value for Precision Biosciences is under review, so past values are not shown until it is resolved.

Source: 10-Q filed November 3, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (1)

Where Precision Biosciences stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $45m, up 3473.0% on a year earlier, against a decline of 11.9% a quarter earlier. Free-cash-flow margin rose to -115.3% from -5084.9% a year earlier. Operating margin widened to -80.8% from -7145.9%. The diluted share count is up 72.5% on a year earlier, which dilutes existing holders. It passes 2 of our 3 financial-health checks.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Precision Biosciences Inc's trailing-twelve-month revenue grew 6353.0% year on year, with a free-cash-flow margin of -115.0%.

Current signal Revenue growth accelerating: TTM revenue growth rose to 6353.0% (+2880.1pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 6353.0% over the last 12 months.
  • Growth speeding up. The growth rate is 2880.1 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 12742.4 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Loss-making. Operating margin is -80.3%: costs exceed revenue.
  • Burning cash. Free cash flow was -115.0% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 18.6% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 72.5% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 69% and a beta of 1.1 against the S&P 500.

Latest results: FY2026 Q3

Filed November 3, 2026
Earnings per share
-$1.26 against an average estimate of -$0.69: missed by 81.7%
Next report
November 3, 2026; average EPS estimate -$0.89

Precision Biosciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.6%
  • 1 week+8.4%
  • 1 month+10.1%
  • This year+67.1%
  • 1 year-14.8%
  • 5 years-97.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$45M
Operating margin
-80.3%
Net margin
-85.6%
EPS (TTM, diluted)
$-3.82

Growth

Revenue growth
+6353.0%
Change in growth rate
+2880.1 pts
Share count change
+72.5%

Cash

Free cash flow (TTM)
-$51.8M
FCF margin
-115.0%
Stock pay % of revenue
18.6%

Earnings

Last results
November 3, 2026
Next results (est.)
January 20, 2027

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Announcement
  3. Results
  4. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Precision Biosciences Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Precision Biosciences Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.01 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$1.9 ~$4.3–$15 Included, half weight
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Precision Biosciences Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2019202020212022202320242025
Share price$416.70$250.20$222.00$35.70$10.95$3.81$4.16
Market value$583m$434m$434m$105m$42m$26m$53m
+ Net debt (− = net cash)−$181m−$90m−$141m−$167m−$117m−$86m−$111m
Enterprise value$402m$344m$293m−$63m−$75m−$60m−$57m
Multiples
Price / sales 0.5x17.9x3.8x4.2x0.9x0.4x1.6x
Price / earnings —————3.7x—
Price / free cash flow ———————
EV / EBITDA ———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

8 /100

Weak moat

How hard Precision Biosciences's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -36.2% of total assets over 8 years.

  • Durability 10 / 20

    Operating margin has been a median -79.3%; its worst year was -12822.6%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 8 years, at a median -153.3% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 813.3% over five years; stock-based pay has been a median 24.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, before the open. Analysts expect revenue of $1m and EPS of −$0.89 (range −$1.19 to −$0.63) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.87 −7% $13m −61%
Next −$1.86 +52% $9m −34%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +78.2% on 90 days ago. In the last 30 days, 0 analysts raised Precision Biosciences Inc's forecast and 3 cut it.

Consensus EPS forecast Precision Biosciences Inc, last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.17 Current fiscal year, 60 days ago: −$2.49 Current fiscal year, 30 days ago: −$2.49 Current fiscal year, 7 days ago: −$3.73 Current fiscal year, Now: −$3.87 −$3.87 Next fiscal year, 90 days ago: −$1.92 Next fiscal year, 60 days ago: −$1.89 Next fiscal year, 30 days ago: −$1.89 Next fiscal year, 7 days ago: −$1.88 Next fiscal year, Now: −$1.86 −$1.86

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.17−$1.92
60 days ago −$2.49−$1.89
30 days ago −$2.49−$1.89
7 days ago −$3.73−$1.88
Now −$3.87−$1.86

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.69 −$1.26 −81.7%
Mar 2026 −$0.81 −$0.75 +7.4%
Dec 2025 −$0.64 $1.01 +256.4%
Sept 2025 −$2.21 −$1.84 +16.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026

No numeric guidance in Precision Biosciences Inc's latest earnings release (filed August 6, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

5 analysts, Oct 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202655
  2. Sep 202655

Counts of recommendations published by analysts covering Precision Biosciences Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.8%
of tradable shares
Days to cover
8.59
at average volume
Short interest, 1 month
+6%
to October 15, 2026
Held by institutions
69%
of shares
Held by insiders
8.0%
of shares
Employees
67
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −14.8%

$8.16 on October 31, 2025 to $6.95

ThenNowEffect
Revenue (last 12 months) $1m $45m +3473.0%
P/S multiple 115.8x 3.7x −96.8%
Share count 18m 24m −25.6%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
DTIL−11%−84%−69%−65%+9%+67%
Industry peers (median)−36%−56%−17%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
DTIL33%17%33%33%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
DTIL−53%−88%−80%−80%−52%−38%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since March 28, 2019: 99% from December 6, 2019 to February 5, 2026. Getting back needed a 16421% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.57 – $9.28
From 52-week high
−25.1%
vs 50-day average
+1.3%
vs 200-day average
+6.1%
Volatility (1 year)
69%
Beta vs S&P 500
1.07

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 7 down
typical move ±7.8%
After a week
3 up, 8 down
typical move ±8.5%
After a month
4 up, 7 down
typical move ±14.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +0.3% +0.5% −2.3% 0.0%
May 5, 2026 −1.4% +2.2% +7.5% −16.0%
March 12, 2026 +12.1% −2.1% +32.8% +40.9%
January 13, 2026 +1.7% −0.7% −1.2% −2.5%
November 3, 2025 −18.0% −1.0% −25.6% −38.0%
August 7, 2025 −8.9% +0.7% −0.8% +3.3%
May 15, 2025 −4.8% +1.1% −6.3% +4.8%
March 26, 2025 −10.8% −1.5% −7.9% +4.7%
January 8, 2025 +19.0% −1.4% −1.5% 0.0%
November 4, 2024 −6.2% +1.0% −7.1% −31.5%
October 24, 2024 −2.1% +0.2% +0.1% −15.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Precision Biosciences Inc
$0 $50M $100M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $48.7M Revenue (TTM), FY24 Q1: $57.5M Revenue (TTM), FY24 Q2: $87.6M Revenue (TTM), FY24 Q3: $75.1M Revenue (TTM), FY24 Q4: $68.7M Revenue (TTM), FY25 Q1: $51.1M Revenue (TTM), FY25 Q2: $1.3M Revenue (TTM), FY25 Q3: $698K Revenue (TTM), FY25 Q4: $34.3M Revenue (TTM), FY26 Q1: $45.1M Revenue (TTM), FY26 Q2: $45.1M Revenue (TTM), FY26 Q3: $45M $45M

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $48.7M
FY24 Q1 $57.5M
FY24 Q2 $87.6M
FY24 Q3 $75.1M
FY24 Q4 $68.7M
FY25 Q1 $51.1M
FY25 Q2 $1.3M
FY25 Q3 $698K
FY25 Q4 $34.3M
FY26 Q1 $45.1M
FY26 Q2 $45.1M
FY26 Q3 $45M
Revenue growth, TTM YoY Precision Biosciences Inc
-2000% 0% 2000% 4000% 6000% 8000% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 94.1% Revenue growth, TTM YoY, FY24 Q1: 88.2% Revenue growth, TTM YoY, FY24 Q2: 88.4% Revenue growth, TTM YoY, FY24 Q3: 43.6% Revenue growth, TTM YoY, FY24 Q4: 41.0% Revenue growth, TTM YoY, FY25 Q1: -11.1% Revenue growth, TTM YoY, FY25 Q2: -98.6% Revenue growth, TTM YoY, FY25 Q3: -99.1% Revenue growth, TTM YoY, FY25 Q4: -50.1% Revenue growth, TTM YoY, FY26 Q1: -11.9% Revenue growth, TTM YoY, FY26 Q2: 3473.0% Revenue growth, TTM YoY, FY26 Q3: 6353.0% 6353.0%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 94.1%
FY24 Q1 88.2%
FY24 Q2 88.4%
FY24 Q3 43.6%
FY24 Q4 41.0%
FY25 Q1 -11.1%
FY25 Q2 -98.6%
FY25 Q3 -99.1%
FY25 Q4 -50.1%
FY26 Q1 -11.9%
FY26 Q2 3473.0%
FY26 Q3 6353.0%
Operating margin (TTM) Precision Biosciences Inc
-15000% -10000% -5000% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -89.8% Operating margin (TTM), FY24 Q1: -60.1% Operating margin (TTM), FY24 Q2: -8.3% Operating margin (TTM), FY24 Q3: -21.6% Operating margin (TTM), FY24 Q4: -38.1% Operating margin (TTM), FY25 Q1: -86.2% Operating margin (TTM), FY25 Q2: -7145.9% Operating margin (TTM), FY25 Q3: -12822.6% Operating margin (TTM), FY25 Q4: -152.2% Operating margin (TTM), FY26 Q1: -86.8% Operating margin (TTM), FY26 Q2: -80.8% Operating margin (TTM), FY26 Q3: -80.3% -80.3%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -89.8%
FY24 Q1 -60.1%
FY24 Q2 -8.3%
FY24 Q3 -21.6%
FY24 Q4 -38.1%
FY25 Q1 -86.2%
FY25 Q2 -7145.9%
FY25 Q3 -12822.6%
FY25 Q4 -152.2%
FY26 Q1 -86.8%
FY26 Q2 -80.8%
FY26 Q3 -80.3%
FCF margin (TTM) Precision Biosciences Inc
-15000% -10000% -5000% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -176.6% FCF margin (TTM), FY24 Q1: -127.2% FCF margin (TTM), FY24 Q2: -75.1% FCF margin (TTM), FY24 Q3: -64.3% FCF margin (TTM), FY24 Q4: -85.4% FCF margin (TTM), FY25 Q1: -114.9% FCF margin (TTM), FY25 Q2: -5084.9% FCF margin (TTM), FY25 Q3: -10521.3% FCF margin (TTM), FY25 Q4: -192.4% FCF margin (TTM), FY26 Q1: -130.4% FCF margin (TTM), FY26 Q2: -115.3% FCF margin (TTM), FY26 Q3: -115.0% -115.0%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -176.6%
FY24 Q1 -127.2%
FY24 Q2 -75.1%
FY24 Q3 -64.3%
FY24 Q4 -85.4%
FY25 Q1 -114.9%
FY25 Q2 -5084.9%
FY25 Q3 -10521.3%
FY25 Q4 -192.4%
FY26 Q1 -130.4%
FY26 Q2 -115.3%
FY26 Q3 -115.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 11 1,070 24 116 25 49 69 34 45
EBITDA −46 −82 −101 −30 −55 −37 −23 −51 −35
Operating income −48 −87 −110 −39 −62 −44 −26 −52 −36
Net income −46 −93 −109 −31 −112 −61 7 −46 −39
Diluted EPS −$87.60 −$66.30 −$62.70 −$15.60 −$38.10 −$15.96 $1.04 −$3.56 —
Growth (year on year)
Revenue — +>999% −97.7% +375.7% −78.3% +94.1% +41.0% −50.1% +>999%
Net income — — — — — — — −738.0% —
Diluted EPS — — — — — — — −442.3% —
Margins
EBITDA margin −418.6% −7.7% −416.1% −26.3% −217.2% −75.8% −33.1% −147.9% −77.8%
Operating margin −440.2% −8.1% −452.2% −34.1% −248.3% −89.8% −38.1% −152.2% −80.3%
Net margin −423.0% −8.7% −448.9% −26.5% −444.8% −125.8% 10.4% −133.4% −85.6%
Free-cash-flow margin −606.5% −8.9% −380.6% −13.8% −195.5% −176.6% −85.4% −192.4% −115.0%
Cash flow
Cash from operations −52 −71 −87 −11 −46 −84 −58 −66 −52
Capital spending 14 25 5 5 3 2 0 0 0
Free cash flow −66 −96 −92 −16 −49 −86 −59 −66 −52
Stock-based pay 2 9 14 17 19 14 13 10 8
Free cash flow after stock pay −68 −105 −106 −32 −68 −100 −71 −76 −60
Balance sheet
Cash 103 181 90 144 190 117 86 111 82
Total debt 0 0 0 2 22 — 0 0 0
Net debt (negative = net cash) −103 −181 −90 −141 −167 −117 −86 −111 −82
Diluted shares — 1m 2m 2m 3m 4m 7m 13m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · September 30, 2026
What it owns · $120m
Short-term assets $87mLonger-term assets $34m
What it owes, and who funded it · $120m
Short-term liabilities $8mLonger-term liabilities $60mShareholders' equity $52m
  • Short-term assets cover short-term liabilities $87m of assets due within a year against $8m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $87m short-term assets against $60m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$36m against $1m of interest.

From Precision Biosciences Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+72.5%
year over year
R&D spending
117.0%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated DTIL STRO SPRO EDIT LXRX OCUL Median
Revenue, last 12 months $45m $46m $47m $47m $41m $52m $55m
Revenue growth, last 12 months >999% −56.3% −3.3% 20.8% −29.0% −8.1% 14.0%
Revenue growth, 3-year average −4.9% −7.0% −4.7% 34.5% 366.7% −1.6% 13.1%
Revenue growth, latest quarter −100.0% −84.6% −100.0% 232.3% −97.6% 0.1% 10.2%
Gross margin — — — — 99.1% 87.1% 82.8%
Operating margin −80.3% −319.6% 12.8% −161.4% −131.4% −603.0% −187.2%
Operating margin, 3-year average <−999% −192.8% −30.8% −365.3% <−999% −397.7% −365.3%
Net margin −85.6% −395.2% 15.7% −157.3% −147.4% −579.1% −163.5%
Cash from operations / revenue −114.9% −317.7% 41.7% −255.0% −156.7% −457.7% −162.3%
Free-cash-flow margin −115.0% −330.9% 41.7% −256.5% −156.7% −490.1% −156.7%
Free-cash-flow margin, 3-year average <−999% −208.2% −12.3% −346.4% <−999% −318.3% −313.4%
Stock pay / revenue 18.6% 14.8% 8.5% 18.4% 30.4% 102.4% 19.2%
Change in share count 72.5% 20.6% 9.1% 21.7% 7.9% 26.4% 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$139M
Institutions reporting
94
Shares held vs prior quarter
▲ 10.4%
Positions opened / closed
31 / 13

Top buyers and sellers, Q2 2026: 61 institutions bought and 27 sold ; the biggest buyer was Blackrock, Inc (+973K shares) and the biggest seller Empery Asset Management, LP (−1.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Aberdeen Group PLC $17.5M 2.2M 12.6% 0.0%
Bleichroeder LP $15.9M 2.0M 11.4% ▲ 21.4%
Octagon Capital Advisors LP $10.6M 1.4M 7.6% ▼ 39.6%
Boothbay Fund Management, LLC $10.6M 1.3M 7.6% ▲ 26.3%
Blackrock, Inc. $9.2M 1.2M 6.6% ▲ 487.1%
Vanguard Capital Management LLC $8.8M 1.1M 6.3% ▲ 22.6%
Lynx1 Capital Management LP $7.5M 950K 5.4% ▼ 3.5%
Driehaus Capital Management LLC $7.4M 947K 5.4% ▼ 4.9%
Empery Asset Management, LP $6.1M 776K 4.4% ▼ 60.6%
Affinity Asset Advisors, LLC $5.1M 647K 3.7% ▲ 8.1%
Geode Capital Management, LLC $4.9M 621K 3.5% ▲ 116.3%
Mackenzie Financial Corp $3.8M 481K 2.7% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Precision Biosciences Inc's complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $63,215 6 trades by 3 insiders, last 12 months Insider sales History → $466,167 11 trades by 4 insiders · 100% under pre-set plans
Net ▼ $402,952 net selling
Insider Date Trade Shares Price Value
Frankel Stanley Director September 28, 2026 Buy 1,000 $6.00 $6,000
Germano Geno J Director September 25, 2026 Buy 2,609 $6.28 $16,385
Brown Melinda Director September 25, 2026 Buy 1,135 $6.27 $7,116
Smith J. Jefferson Chief Research Officer February 18, 2026 Sell pre-set plan 4,925 $3.84 $18,912
Scimeca Dario General Counsel and Secretary February 18, 2026 Sell pre-set plan 4,925 $3.84 $18,912
Kelly John Alexander Chief Financial Officer February 18, 2026 Sell pre-set plan 8,149 $3.84 $31,292
Amoroso Michael President and CEO February 18, 2026 Sell pre-set plan 20,559 $3.84 $78,947
Amoroso Michael President and CEO January 22, 2026 Sell pre-set plan 34,799 $4.17 $145,112
Smith J. Jefferson Chief Research Officer January 21, 2026 Sell pre-set plan 10,200 $4.03 $41,106
Kelly John Alexander Chief Financial Officer January 21, 2026 Sell pre-set plan 15,213 $4.03 $61,308
Scimeca Dario General Counsel and Secretary January 21, 2026 Sell pre-set plan 8,854 $4.03 $35,682
Frankel Stanley Director December 16, 2025 Buy 2,700 $4.70 $12,690

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 20, 2027 estimated from the company's past filing pattern, not announced

  • November 3, 2026
  • August 6, 2026
  • May 5, 2026
  • March 12, 2026
  • January 13, 2026
  • November 3, 2025

Recent SEC filings

Data status

When each part of this page on Precision Biosciences Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Precision Biosciences Inc in brief

What does Precision Biosciences Inc do?
Precision Biosciences Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Precision Biosciences Inc's stock ticker?
Precision Biosciences Inc trades under the ticker DTIL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Precision Biosciences Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Precision Biosciences Inc reported revenue of $45M, 6353.0% higher than a year earlier, according to its SEC filings.
What is Precision Biosciences Inc's free cash flow?
Precision Biosciences Inc's free-cash-flow margin is -115.0% of revenue over the trailing twelve months.
Who are Precision Biosciences Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Aberdeen Group PLC, Bleichroeder LP and Octagon Capital Advisors LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Precision Biosciences Inc's market cap?
On December 31, 2025, Precision Biosciences Inc's market capitalisation was about $53.4M and net debt of -$111M. Market figures come from third-party market data and may be delayed.
Who are Precision Biosciences Inc's competitors?
In our Biotechnology peer group, the companies closest to Precision Biosciences Inc are Sutro Biopharma, Inc., Spero Therapeutics, Inc., Editas Medicine, Inc., Lexicon Pharmaceuticals, Inc. and Ocular Therapeutix, Inc. The side-by-side comparison below sets their revenue, margins and growth against Precision Biosciences Inc's.
Are insiders buying or selling Precision Biosciences Inc stock?
Over the last 12 months, Precision Biosciences Inc's directors and officers reported 6 open-market purchases and 11 sales on Form 4. The insider trading page charts every trade.
When is Precision Biosciences Inc's next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Precision Biosciences Inc announces its own schedule.